

Clinical trials of All mechanism for melanoma in previously untreated advanced melanoma

TrialResults-center www.trialresultscenter.org

1 anti-PD-1 antibody

Trial	Treatments	Patients	Trials design and methods
nivolumab vs dacarbazine			
CheckMate 066 (Robert) , 2015 [NCT01721772] n=NA follow-up:	nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks versus dacarbazine at a dose of 1000 mg per square meter of body-surface area every 3 weeks	previously untreated patients who had unresectable metastatic melanoma without a BRAF mutation (stage III or IV)	double-blind
nivolumab + ipilimumab vs ipilimumab			
CheckMate 067 (nivo + ipi) , 2015 [NCT01844505] n=314/315 follow-up:	Nivolumab + ipilumab versus Ipilimumab alone	Previously Untreated Advanced Melanoma	Parallel groups double-blind

References

CheckMate 066 (Robert), 2015:

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebb C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015 Jan 22;372:320-30 [25399552] [10.1056/NEJMoa1412082](https://doi.org/10.1056/NEJMoa1412082)

CheckMate 067 (nivo + ipi), 2015:

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 May 31; [26027431] [10.1056/NEJMoa1504030](https://doi.org/10.1056/NEJMoa1504030)

2 antiCTLA-4 antibody

Trial	Treatments	Patients	Trials design and methods
ipilimumab 10mg/kg plus dacarbazine vs dacarbazine			

continued...

Trial	Treatments	Patients	Trials design and methods
Robert (Ipilimumab) , 2011 [NCT00324155] n=NA follow-up:	ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) versus dacarbazine (850 mg per square meter)	patients with previously untreated metastatic melanoma (stage III (unresectable) or stage IV)	double blind

References

Robert (Ipilimumab), 2011:

Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517-26 [[21639810](#)]

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.